Brokerages Set CytomX Therapeutics Inc (CTMX) Target Price at $31.75

CytomX Therapeutics Inc (NASDAQ:CTMX) has been given a consensus rating of “Buy” by the twelve brokerages that are presently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $31.75.

Several research firms recently commented on CTMX. Zacks Investment Research upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research report on Tuesday, January 8th. BidaskClub upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. ValuEngine lowered shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Goldman Sachs Group upgraded shares of CytomX Therapeutics from a “neutral” rating to a “buy” rating in a research report on Thursday, December 13th. Finally, Piper Jaffray Companies began coverage on shares of CytomX Therapeutics in a research report on Sunday, December 2nd. They set an “overweight” rating and a $13.24 price target on the stock.

In other news, CFO Debanjan Ray sold 3,000 shares of CytomX Therapeutics stock in a transaction dated Wednesday, December 12th. The shares were sold at an average price of $15.00, for a total value of $45,000.00. Following the sale, the chief financial officer now owns 8,928 shares in the company, valued at $133,920. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 8.50% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC grew its position in shares of CytomX Therapeutics by 15.4% in the third quarter. FMR LLC now owns 6,744,553 shares of the biotechnology company’s stock valued at $124,774,000 after purchasing an additional 900,927 shares during the period. BlackRock Inc. grew its position in shares of CytomX Therapeutics by 19.9% in the third quarter. BlackRock Inc. now owns 3,868,566 shares of the biotechnology company’s stock valued at $71,570,000 after purchasing an additional 642,165 shares during the period. Perceptive Advisors LLC grew its position in shares of CytomX Therapeutics by 38.5% in the third quarter. Perceptive Advisors LLC now owns 2,661,715 shares of the biotechnology company’s stock valued at $49,242,000 after purchasing an additional 740,000 shares during the period. Vanguard Group Inc. grew its position in shares of CytomX Therapeutics by 18.3% in the third quarter. Vanguard Group Inc. now owns 2,504,987 shares of the biotechnology company’s stock valued at $46,343,000 after purchasing an additional 387,722 shares during the period. Finally, Vanguard Group Inc grew its position in shares of CytomX Therapeutics by 18.3% in the third quarter. Vanguard Group Inc now owns 2,504,987 shares of the biotechnology company’s stock valued at $46,343,000 after purchasing an additional 387,722 shares during the period. Institutional investors and hedge funds own 83.93% of the company’s stock.

CTMX stock opened at $18.97 on Wednesday. The firm has a market cap of $857.84 million, a P/E ratio of -16.35 and a beta of 0.91. CytomX Therapeutics has a one year low of $12.51 and a one year high of $35.00.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Further Reading: What is the NASDAQ Stock Market?

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply